William Blair Keeps Buy Rating for Amgen Despite Moderate Analyst Performance

William Blair analyst Matt Phipps has maintained his buy rating for Amgen (AMGN.US). This decision is based on Phipps' analysis of the company's performance, which TipRanks data suggests has been accurate in the past. According to TipRanks, Phipps has a success rate of 46.7% and an average return of 4.0% over the past year.

The analyst's ratings are calculated based on their historical performance, with a 5-star rating indicating exceptional accuracy. In this case, Phipps' 3-star rating suggests that his predictions have been somewhat accurate but not exceptional. It is worth noting that TipRanks data provides an independent evaluation of financial analysts' recommendations.